1. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Issue 2 (February 2016) Authors: Chanan-Khan, Asher; Cramer, Paula; Demirkan, Fatih; Fraser, Graeme; Silva, Rodrigo Santucci; Grosicki, Sebastian; Pristupa, Aleksander; Janssens, Ann; Mayer, Jiri; Bartlett, Nancy L; Dilhuydy, Marie-Sarah; Pylypenko, Halyna; Loscertales, Javier; Avigdor, Abraham; Rule, Simon; Villa, Diego; Samoil... Journal: Lancet oncology Issue: Volume 17:Issue 2(2016:Feb.) Page Start: 200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Issue 8 (August 2014) Authors: Eketorp Sylvan, Sandra; Hansson, Lotta; Karlsson, Claes; Norin, Stefan; Lundin, Jeanette; Österborg, Anders Journal: Leukemia & lymphoma Issue: Volume 55:Issue 8(2014:Aug.) Page Start: 1774 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗